Objective: Converging lines of evidence indicate that defects in the mitochondrial electron transport chain (ETC) are associated with bipolar disorder (BD), and that mood-stabilizing drugs produce neuroprotective effects. Our objective is to review the most recent findings regarding this research.
B D affects about 1.5% of the population and is characterized by episodes of acute mania and depression with significant morbidity and mortality. The suicide rate among bipolar patients is 10% to 15%, 15 times that of the general population. The disorder frequently brings about serious impairment of social functioning and health-related quality of life, dependence on social welfare, intervention by the criminal justice system, and an economic burden to patients, families, and society. [1] [2] [3] [4] Although genetic factors have been considerably implicated, our understanding of the cause of BD remains incomplete. Many researchers using neuroimaging and postmortem brain tissue in their studies have detected brain damage, particularly cell loss and atrophy in prefrontal and limbic brain regions, in BD subjects. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In recent years, the possibility that mitochondrial dysfunction plays a role in the disorder's pathologic mechanism has attracted much attention.
The major component of mitochondria is the ETC, consisting of a series of multimeric protein complexes. Mitochondrial ETC creates a proton gradient for generating energy in the form of ATP through the process of oxidative phosphorylation. Its normal functioning is essential to providing the energy for brain functioning. A dysfunctional mitochondrial ETC will generate excessive ROS that subsequently cause oxidative damage. [16] [17] [18] Mitochondria regulate processes of cell death and survival via their role in energy metabolism, therefore, mitochondrial dysfunction may act in BD to generate brain damage and lead to cell loss and brain atrophy. Here, we review recent findings pertaining to mitochondrial dysfunction, particularly focusing on defects of mitochondrial ETC in BD and on the antioxidative properties of currently used mood-stabilizing drugs.
Mitochondrial Dysfunction and Cell Damage
Mitochondria are composed of outer and inner membranes with many enzymes involved in energy production and molecular transport. The major role for the mitochondria is generation of ATP via mitochondrial ETC enzyme complexes I to IV and ATP-synthase (also called complex V). Protons from oxidation of fuel molecules are transferred across the inner mitochondrial membrane by ETC complex I-IV, a process that generates an electrochemical proton gradient that powers ATP synthesis in complex V via oxidative phosphorylation.
Mitochondria play a critical role in the regulation of the cellular redox state. When mitochondrial ETC generates the electrochemical proton gradient that drives ATP synthesis, it also induces production of ROS. The major sources of mitochondrial ROS production are the ubiquinone sites in complexes I and III. [16] [17] [18] [19] Because mitochondrial ETC is responsible for most oxygen consumption, it is a major source of ROS production. ROS react with many biological molecules, including DNA, proteins, and lipids, subsequently causing DNA mutation, protein cleavage, and lipid peroxidation. [20] [21] [22] Brain cells are more vulnerable to oxidative damage because the brain consumes about 20% of total body oxygen although constituting less than 2% of total body weight. The major constituents of neuronal cell membranes are polyunsaturated fatty acids that act as a substrate for ROS. 22 A series of natural antioxidant defence systems, including superoxide dismutase, catalase, glutathione, glutathione peroxidase, and GST, normally eliminate ROS production and limit tissue damage. Therefore, oxidative damage results from mitochondrial dysfunction-induced ROS overproduction that overwhelms the cellular antioxidant capacity. Oxidative damage in the brain is seen in a number of neurological disorders including Parkinson disease and Alzheimer disease, [23] [24] [25] [26] [27] and in schizophrenia. 28, 29 The significance of oxidative damage as a component of most disease processes in the central nervous system is increasingly recognized.
Mitochondria also regulate intracellular calcium homeostasis. Calcium is an important second messenger that regulates synaptic plasticity in neuronal cells. It has been acknowledged that calcium signals can be greatly influenced by mitochondrial calcium uptake via the uniporter and by mitochondrial calcium efflux via the permeability transition pore. 30, 31 The mitochondrial membrane potential generated by the ETC proton gradient is key to mitochondrial calcium uptake and efflux. Mitochondrial dysfunction changes the mitochondrial membrane potential, reduces its ability to perform calcium sequestration, and disturbs calcium homeostasis, which result in cell damage. In addition, mitochondria play an important role in regulating the process of apoptosis. Cytochrome c is a component of the mitochondrial ETC complexes. When mitochondrial dysfunction induces changes of mitochondrial membrane potential, cytochrome c is leaked into the cytosol from mitochondria. The leaked cytochrome c stimulates the apoptosis process by binding its adaptor Apaf-1 and activating pro-caspase-9. Activation of caspase-9 further activates 
Evidence of Mitochondrial Dysfunction in Bipolar Disorder
Several studies in which researchers use neuroimaging and postmortem brain tissue have revealed that brain volume and the number of neuronal and glial cells are reduced in prefrontal and limbic brain regions of patients with BD.
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These findings suggest that brain damage may be involved in the pathologic development of this disease. Increasing evidence has shown that mitochondrial dysfunction is associated with BD in these brain regions. This evidence includes indications of increased anaerobic glycolysis and impaired phospholipid metabolism and calcium homeostasis.
Studies in which researchers use MRS have shown that phosphocreatine and ATP are decreased in the frontal lobes and basal ganglia in patients with mood disorders. [33] [34] [35] [36] [37] [38] [39] Phosphocreatine is a high-energy compound made from creatine and ATP. Decrease of phosphocreatine and ATP suggests impaired energy production caused by mitochondrial dysfunction. MRS studies have also shown decreased pH in BD patients' brains. 40 -42 Studies using postmortem brain tissue also indicate lower pH values in BD subjects when compared with controls. 43 In addition, lactate levels were also shown to be increased in grey matter of patients with BD. 44 These findings suggest that mitochondrial dysfunction induces an energy production shift from more efficient oxidative phosphorylation in mitochondrial ETC to less efficient anaerobic glycolysis, resulting in increased lactate levels and decreased pH value. One consequence of decreased mitochondrial energy production may be impaired phospholipid metabolism, because maintenance of brain cell membrane requires 10% to 15% of all ATP production in the brain. 45 Decreased mitochondrial energy production also changes the mitochondrial membrane potential that inhibits mitochondrial capability for calcium sequestration. Indeed, many MRS studies have indicated abnormal phospholipid metabolism in BD subjects' brains that includes alteration in levels of choline, myo-inositol, inositol monophosphates, and phosphomonoesters. 37, 40, [46] [47] [48] [49] [50] [51] Altered intracellular free calcium levels have been found in blood cells and olfactory neurons from patients with BD. [52] [53] [54] [55] These findings together indicate that BD may be a disease of mitochondrial dysfunction and impaired systems of energy production.
Mitochondrial Electron Transport Chain Complexes and Bipolar Disorder
Mitochondrial ATP is produced via the process of oxidative phosphorylation coupled to the mitochondrial ETC enzyme complexes. Genes of the mitochondrial ETC complexes are distributed throughout nuclear and mitochondrial DNA. Studies in which researchers use molecular biologic and molecular genetic approaches indicate the presence of deletion, mutation, and abnormal expression in the mitochondrial ETC complex genes.
By examining the concentration of the 4977-base pair deletion in mitochondrial DNA with a quantitative PCR method, Kato et al, 56 in 1997, first reported that deletion of mitochondrial DNA was significantly higher in postmortem cerebral cortex of BD subjects than in age-matched controls. Several years later, growing evidence indicates association between BD and the mutations-polymorphisms of mitochondrial DNA. Human mitochondrial DNA encode 13 subunits of mitochondrial ETC complexes, including 7 subunits of complex I. Studies have shown that the polymorphisms of mitochondrial DNA coding complex I genes are significantly associated with BD. Kato et al 5 7 , 5 8 analyzed the polymorphisms of mitochondrial DNA in BD patients and found that polymorphisms 5178C and 10398A were significantly associated with BD.
Mitochondrial 5178C is involved in a methionine to leucine substitution, while 10398A causes a substitution of threonine for alanine. 59, 60 These substitutions of amino acids alter the structure of complex I subunits ND2 and ND3. Munakata et al 61 identified a rare missense mutation, 3644T®C, when they examined the entire sequence of the mitochondrial genome in 6 BD patients with comorbid somatic symptoms suggestive of mitochondrial disorders. The 3644C converts amino acid valine to alanine in subunit I of complex I. They further found that 3644C mutation is significantly associated with BD, and that 3644C mutation was liable to decrease complex I activity and mitochondrial membrane potential. This finding suggests that 3644C mutation has a functional influence on mitochondria in subjects with BD.
Complex I is a large and complex enzyme consisting of 45 subunits. Seven subunits are encoded by mitochondrial DNA, while nuclear DNA encodes the majority of subunits. Washizuka et al 62, 63 have genotyped complex I subunit NDUFV2 in BD patients and found that polymorphisms of -602G and -3542G in the upstream promoter region of NDUFV2 are associated with BD. The promoter activity in -602A mutation was found to be lower than in -602G. They These findings together suggest that the mitochondrial ETC complex I is a genetic risk factor for BD and plays an important role in the pathologic development of this disorder. Complex I catalyzes the transfer of electrons from reduced nicotinamide adenine dinucleotide to ubiquinone. This reaction is coupled to translocation of protons across the mitochondrial inner membrane and helps to build the electrochemical potential needed to produce ATP. Complex I is one of the main sites where electrons are leaked to oxygen, resulting in production of ROS that cause oxidative damage. 67 Abnormal function of complex I in BD suggests ROS overproduction that induces oxidative damage in this disease.
Recent studies using microarray analysis have also shown that mitochondrial ETC complexes are downregulated in postmortem brain tissue in subjects with BD. Konradi et al, 68 using
Affymetrix oligonucleotide array in postmortem hippocampus from the Harvard Brain Tissue Resource Center, analyzed gene expression profiles in 3 groups including a BD group, a schizophrenia group, and a healthy control group, with 8 to 10 subjects for each group. They found that expression of many mRNAs coding for complexes I-V subunits was significantly decreased in subjects with BD, but not in those with schizophrenia when compared with controls. Iwamoto et al 69 also
used Affymetrix oligonucleotide array to analyze gene expression profiles in postmortem frontal cortex of a large group of BD subjects (35 subjects for each group) provided by Stanley Foundation Array Collection. They found that many mitochondria-related genes, including genes of ETC complexes, showed downregulation in BD when compared with control subjects. Recently, Sun et al 3 used human 19K
high-density cDNA spot microarrays to analyze expression profiles on the same postmortem frontal cortex brain tissue from Stanley Foundation Array Collection and found that 23 genes related to mitochondria, including 8 genes coding subunits of complex I, III, IV, and V of the mitochondrial ETC, were differentially expressed between BD and control groups. These 8 genes are NDUFS7 and NDUFS8 (complex I), UQCRC2 (complex III), COX5A and COX6C (complex IV), and ATP5C1, ATP5J and ATP5G3 (complex V). All of these 8 genes are downregulated in BD subjects. Four of these genes were also found to be downregulated in postmortem hippocampus of BD subjects by a previous study. 68 The decreased mRNA levels of the complex I subunit NDUFS7 were further verified in BD subjects using real-time quantitative PCR.
NDUFS7 is located at chromosome 19p13. Recent genome-wide linkage scans in a large group of BD samples from the NIMH genetics initiative suggests linkage of chromosome 19p13 in BD. 70 Altogether these results suggest that NDUFS7 plays an important role in the etiology of BD. These findings from different tissue samples, brain regions, and array methodologies provide converging evidence that pathology of BD may involve defects of mitochondrial ETC complexes, resulting in abnormal energy metabolism and ROS overproduction. Findings of defects in mitochondrial ETC complexes are summarized in Table 1 .
Insufficient endogenous antioxidant defence also enhances oxidative damage. Superoxide dismutase, catalase, GST, and glutathione peroxidase are components of the antioxidant defence system. It was reported that expression of superoxide dismutase-1, microsomal GST, GST-P1, and glutathione peroxidase-4 are decreased in postmortem frontal cortex from BD subjects. 43, 71 Benes et al 72 reported that expression of GST-A4 and -M3, and glutathione peroxidase-1 and -4 are reduced in postmortem hippocampus from BD subjects. Decreased expression may lead to deficiency of these antioxidant enzymes. Indeed, decreased activities of superoxide dismutase and catalase in plasma have been found in BD subjects. 73, 74 Whether decreased expression of components of ETC complex and antioxidant enzymes in BD subjects contributes to ROS overproduction that causes oxidative damage requires further investigation. Additionally, increased oxidative damage to lipid has been consistently found in blood samples of patients with BD. [73] [74] [75] Frey et al 76 recently investigated oxidative damage in 2 monozygotic twins during a manic episode. They found that these bipolar twins had higher lipid peroxidation than healthy controls and were normalized after mood-stabilizer treatment. This suggests that oxidative damage may play a role in the pathophysiology of BD and that pharmacological treatment may exert antioxidant effects. These findings together suggest that oxidative damage may be induced by impaired mitochondrial ETC componentsinduced ROS overproduction and (or) deficient antioxidant capacity in BD, and that the process of oxidative damage may be a target for mood-stabilizing treatment.
Mood-Stabilizing Drugs and Oxidative Damage
The mood-stabilizing drugs are useful for treatment of acute manic episodes and for prophylaxis against future episodes. However, despite many years research, the mood-stabilizing mechanism of these drugs is not yet clear. Current moodstabilizing drugs have a significant degree of efficacy for BD treatment, but they also have side effects including weight gain, nausea, tremor, reduced sexual drive or performance, anxiety, hair loss, movement problems, and dry mouth, among others. There is a clear need to develop novel and more effective therapeutics for BD treatment. Therefore, understanding the mood-stabilizing mechanism and developing new drugs that act directly on the mechanisms of BD pathology will be critical to improving treatment for this disorder and mitigating side effects.
As reviewed above, mitochondrial ETC defects in BD that induce ROS overproduction together with deficiency in the endogenous antioxidant defence system may cause subsequent oxidative damage. These findings indicate that the process of oxidative damage may be a therapeutic target for mood-stabilizing drugs and such therapies could be beneficial in the treatment of BD. 
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Rotenone blocks the transfer of electrons from Fe-S centres in complex I to ubiquinone and is an inhibitor for complex I. This drug is able to induce oxidative damage by enhancing mitochondrial ROS production via inhibition of complex I activity. 83 King 87 discovered that the expression of 3 GST isoenzymes including GST M1, A3, and A4 were regulated by chronic treatment with the moodstabilizing drug valproate at a therapeutically relevant concentration in primary cultured rat cerebral cortical cells. Regulation of GST M1, A3, and A4 was verified using northern blotting hybridization. Chronic valproate treatment increased mRNA levels of M1 and A4, but decreased the A3 mRNA level. GST activity was also increased dose-and time-dependently by chronic valproate treatment. Chronic treatment with lithium has also been found to increase expression of GST M1 and A4, and GST enzyme activity in primary cultured rat cerebral cortical cells. 87, 88 GST is a family of detoxification enzymes that include multiple isoforms. As components of the cellular antioxidant system, they catalyze the conjugation of certain electrophiles, including oxidized products generated by ROS, with thiolate anion of the reduced glutathione, an essential brain antioxidant, to form a nontoxic and excretable product. 89 This detoxification process is now believed to play critical roles in combating oxidative stress and cell toxicity in the brain. Recently, Cui et al 81 found that chronic treatment with lithium and valproate significantly increased glutathione levels in rat cerebral cortical cells. They also found that expression of its rate-limiting synthesis enzyme (glutamate-cysteine ligase) and that depletion of glutathione reduced the neuroprotective effect of lithium and valproate against reactive oxygen specie H 2 O 2 -induced cell death.
These results suggest that glutathione plays an important role in the neuroprotective effect of lithium and valproate against oxidative damage. The findings that lithium and valproate increase both glutathione levels and GST activity are significant and important because they are consistent with the previous finding that chronic lithium and valproate treatment inhibit oxidative damage to lipid and protein in rat cerebral cortical cells. These findings indicate that lithium and valproate may be able to accelerate the process of GSTcatalyzed GSH conjugation to limit oxidative damage.
Mood-stabilizing drugs have also been shown to regulate other components of the antioxidant defence system. Shukla 90 reported that intraperitoneal administration of lithium for 1 day or 3 days increased the activity of superoxide dismutase in rat brain. Table 2 .
In addition, a number of studies have also indirectly indicated that mood-stabilizing drugs have antioxidative properties. It has been reported that chronic treatment with valproate increased endoplasmic reticulum stress protein GRP78, and closely related proteins GRP94 and calreticulin, in rat cerebral cortex. 95, 96 Recently, chronic treatment with lithium was also shown to increase expression of GRP78, GRP94, and calreticulin in primary cultured rat cerebral cortical cells and PC12 cells. 97, 98 GRP78 functions to bind Ca 2+ and fold damaged proteins. 99, 100 It has been found to inhibit oxygen free radical accumulation and stabilize mitochondria functioning. 100, 101 A number of studies also showed that chronic treatment with lithium and valproate increased expression of the antiapoptotic factor bcl-2 in rat cerebral cortex. 98, 102, 103 Bcl-2 was also shown to decrease ROS generation by stabilizing the inner transmembrane potential of mitochondria.
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The c-Jun N-terminal kinase pathway is known to mediate oxidative toxicity. Chronic lithium treatment was shown to inhibit glutamate and abeta -induced activation of c-Jun N-terminal kinase, 106, 107 indicating this kinase is also a target for lithium. All of these findings suggest that lithium and valproate produce neuroprotective effects against oxidative damage by regulating various targets. First, lithium and valproate may increase scavenging of oxidized products by regulating the glutathione-GST detoxification process. Second, these drugs may be able to stabilize mitochondrial function by regulating Bcl-2 and GRP78. In addition, lithium may also increase scavenging of H 2 O 2 by regulating superoxide dismutase, glutathione and glutathione peroxidase, and downstream signalling c-Jun N-terminal kinase that mediates oxidative stress-induced cell death.
The neuroprotective effects of mood-stabilizing drugs against oxidative damage have been recognized only in the last few years. Although there is presently no available data directly connecting that neuroprotective effect to treatment for BD with these drugs, the concept is supported by numerous studies demonstrating mitochondrial dysfunction, and significant reductions in regional central nervous system volume and cell number associated with mood disorder. If the neuroprotective effect of mood-stabilizing drugs against oxidative damage plays a role in the pharmacological treatment of BD, antioxidants could be beneficial for patients with this disorder. It has been reported that agomelatine, an effective antioxidant that scavenges free radicals, is effective in treating major depressive disorder and BD. 108, 109 More clinical studies will be necessary to clearly demonstrate whether these treatments do indeed reduce or delay brain damage in mood disorder patients. Nevertheless, an alternative antioxidative approach may lead to novel therapeutic targets acting directly on the mechanisms of bipolar pathology for clinical trial investigation in the near future, which could ultimately lead to producing improved drugs with fewer side effects for bipolar treatment.
Summary
Converging lines of evidence have shown deletion, mutation, and decreased expression of mitochondrial ETC complexes in BD. Defects of mitochondrial ETC complexes, together with decreased expression of antioxidant enzymes, indicate the possible involvement of oxidative damage in this disorder. These findings raise the possibility that the process of oxidative damage could be a significant therapeutic target for the treatment of BD with mood-stabilizing drugs. Recent studies demonstrate that mood-stabilizing drugs produce neuroprotective effects against oxidative damage in rat brain. In addition, mood-stabilizing drugs regulate glutathione-GST and other antioxidant defence pathways, indicating that alternative therapy that includes agents with antioxidative properties may be an effective approach for the treatment of BD. Whether oxidative damage in specific brain regions is critical in the development of BD, and if antioxidative treatment has therapeutic efficacy, require further clinical investigation. Résultats : Il y a suppression, mutation, et une expression réduite des complexes de la CTE mitochondriale dans le TB. Parce que la CTE est une source majeure des espèces réactives oxygénées, ces facteurs, de concert avec l'expression réduite des enzymes antioxidantes du TB, suggèrent la présence de dommages oxydatifs dans ce trouble. De nombreuses études récentes ont démontré que les médicaments psychorégulateurs produisent des effets neuroprotecteurs contre les dommages oxydatifs et qu'ils accroissent l'expression et les activités des enzymes antioxidantes endogènes dans le cerveau des rats.
Conclusion :
Ces résultats indiquent que le processus des dommages oxydatifs pourrait être une cible thérapeutique importante pour le traitement du TB au moyen de médicaments psychorégulateurs.
